CN112137095A - 一种运动营养组合物及其制备方法 - Google Patents
一种运动营养组合物及其制备方法 Download PDFInfo
- Publication number
- CN112137095A CN112137095A CN202011036955.4A CN202011036955A CN112137095A CN 112137095 A CN112137095 A CN 112137095A CN 202011036955 A CN202011036955 A CN 202011036955A CN 112137095 A CN112137095 A CN 112137095A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- sports
- nutritional composition
- parts
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000000284 extract Substances 0.000 claims abstract description 47
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 40
- 235000010755 mineral Nutrition 0.000 claims abstract description 40
- 239000011707 mineral Substances 0.000 claims abstract description 40
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000005715 Fructose Substances 0.000 claims abstract description 26
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229940088594 vitamin Drugs 0.000 claims abstract description 24
- 229930003231 vitamin Natural products 0.000 claims abstract description 24
- 235000013343 vitamin Nutrition 0.000 claims abstract description 24
- 239000011782 vitamin Substances 0.000 claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 22
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 18
- 235000014676 Phragmites communis Nutrition 0.000 claims abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 18
- 239000011734 sodium Substances 0.000 claims abstract description 18
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 18
- 244000068988 Glycine max Species 0.000 claims abstract description 17
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 17
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 17
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 17
- 235000021307 Triticum Nutrition 0.000 claims abstract description 17
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 16
- 229960003624 creatine Drugs 0.000 claims abstract description 15
- 239000006046 creatine Substances 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 241000508725 Elymus repens Species 0.000 claims abstract description 12
- 229960003080 taurine Drugs 0.000 claims abstract description 12
- MLIKYFGFHUYZAL-UHFFFAOYSA-K trisodium;hydron;phosphonato phosphate Chemical compound [Na+].[Na+].[Na+].OP([O-])(=O)OP([O-])([O-])=O MLIKYFGFHUYZAL-UHFFFAOYSA-K 0.000 claims abstract description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000013361 beverage Nutrition 0.000 claims abstract description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 30
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 28
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 28
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 26
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 19
- 239000008103 glucose Substances 0.000 claims description 19
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 16
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 229930003427 Vitamin E Natural products 0.000 claims description 15
- 229940024606 amino acid Drugs 0.000 claims description 15
- 235000001014 amino acid Nutrition 0.000 claims description 15
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 15
- 235000019165 vitamin E Nutrition 0.000 claims description 15
- 239000011709 vitamin E Substances 0.000 claims description 15
- 229940046009 vitamin E Drugs 0.000 claims description 15
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 14
- 229930003451 Vitamin B1 Natural products 0.000 claims description 14
- 229930003268 Vitamin C Natural products 0.000 claims description 14
- 239000001103 potassium chloride Substances 0.000 claims description 14
- 235000011164 potassium chloride Nutrition 0.000 claims description 14
- 229960003495 thiamine Drugs 0.000 claims description 14
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 14
- 235000010374 vitamin B1 Nutrition 0.000 claims description 14
- 239000011691 vitamin B1 Substances 0.000 claims description 14
- 235000019154 vitamin C Nutrition 0.000 claims description 14
- 239000011718 vitamin C Substances 0.000 claims description 14
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 13
- 239000013535 sea water Substances 0.000 claims description 13
- 235000019158 vitamin B6 Nutrition 0.000 claims description 13
- 239000011726 vitamin B6 Substances 0.000 claims description 13
- 229940011671 vitamin b6 Drugs 0.000 claims description 13
- 229930091371 Fructose Natural products 0.000 claims description 12
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 12
- 235000014633 carbohydrates Nutrition 0.000 claims description 12
- 239000011777 magnesium Substances 0.000 claims description 12
- 229910052749 magnesium Inorganic materials 0.000 claims description 12
- 235000013336 milk Nutrition 0.000 claims description 12
- 239000008267 milk Substances 0.000 claims description 12
- 210000004080 milk Anatomy 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000004475 Arginine Substances 0.000 claims description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 11
- 229960003121 arginine Drugs 0.000 claims description 11
- 235000021552 granulated sugar Nutrition 0.000 claims description 11
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 9
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 9
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 claims description 9
- 229960005261 aspartic acid Drugs 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 8
- 229930182844 L-isoleucine Natural products 0.000 claims description 8
- 239000004395 L-leucine Substances 0.000 claims description 8
- 235000019454 L-leucine Nutrition 0.000 claims description 8
- 229960000310 isoleucine Drugs 0.000 claims description 8
- 229960003136 leucine Drugs 0.000 claims description 8
- 229960004295 valine Drugs 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 7
- 235000015203 fruit juice Nutrition 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 6
- 239000001177 diphosphate Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 claims description 5
- 239000000686 essence Substances 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 3
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 235000021014 blueberries Nutrition 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- TZPGTGQRVXSGQM-HTKRKRNRSA-K trisodium;[(2r,3s,4s,5r)-3,4,5-trihydroxy-5-[[hydroxy(oxido)phosphoryl]oxymethyl]oxolan-2-yl]methyl phosphate Chemical compound [Na+].[Na+].[Na+].O[C@H]1[C@H](O)[C@@](O)(COP([O-])([O-])=O)O[C@@H]1COP(O)([O-])=O TZPGTGQRVXSGQM-HTKRKRNRSA-K 0.000 claims description 3
- 235000004936 Bromus mango Nutrition 0.000 claims description 2
- 235000005979 Citrus limon Nutrition 0.000 claims description 2
- 244000131522 Citrus pyriformis Species 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 240000007228 Mangifera indica Species 0.000 claims description 2
- 235000014826 Mangifera indica Nutrition 0.000 claims description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 2
- 235000009184 Spondias indica Nutrition 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 229930003471 Vitamin B2 Natural products 0.000 claims description 2
- 239000006286 aqueous extract Substances 0.000 claims description 2
- 229960002173 citrulline Drugs 0.000 claims description 2
- 235000013477 citrulline Nutrition 0.000 claims description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 2
- 235000019674 grape juice Nutrition 0.000 claims description 2
- 235000015201 grapefruit juice Nutrition 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 235000005152 nicotinamide Nutrition 0.000 claims description 2
- 239000011570 nicotinamide Substances 0.000 claims description 2
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 235000015205 orange juice Nutrition 0.000 claims description 2
- 235000013944 peach juice Nutrition 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019164 vitamin B2 Nutrition 0.000 claims description 2
- 239000011716 vitamin B2 Substances 0.000 claims description 2
- CEHGLSKJDFICTB-PWVOXRODSA-K D-Fructose 1,6-bisphosphate trisodium salt Chemical compound [Na+].[Na+].[Na+].[O-]P(=O)([O-])OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)COP(O)([O-])=O CEHGLSKJDFICTB-PWVOXRODSA-K 0.000 claims 1
- 240000007171 Imperata cylindrica Species 0.000 claims 1
- 244000098338 Triticum aestivum Species 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 20
- 241000209140 Triticum Species 0.000 abstract description 16
- 210000003205 muscle Anatomy 0.000 abstract description 16
- -1 compound amino acid Chemical class 0.000 abstract description 12
- 239000002131 composite material Substances 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 8
- 239000003094 microcapsule Substances 0.000 abstract description 8
- 235000015097 nutrients Nutrition 0.000 abstract description 6
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 4
- 230000001934 delay Effects 0.000 abstract description 3
- 230000037149 energy metabolism Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 description 43
- 241000699670 Mus sp. Species 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 20
- 229920002527 Glycogen Polymers 0.000 description 19
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 19
- 102000019197 Superoxide Dismutase Human genes 0.000 description 19
- 108010012715 Superoxide dismutase Proteins 0.000 description 19
- 229940096919 glycogen Drugs 0.000 description 19
- 229940118019 malondialdehyde Drugs 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 14
- 235000000346 sugar Nutrition 0.000 description 14
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 239000001301 oxygen Substances 0.000 description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000004060 metabolic process Effects 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 230000009182 swimming Effects 0.000 description 11
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000013589 supplement Substances 0.000 description 10
- 239000003792 electrolyte Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- 206010021143 Hypoxia Diseases 0.000 description 8
- 240000003444 Paullinia cupana Species 0.000 description 8
- 235000000556 Paullinia cupana Nutrition 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 241001598107 Imperata Species 0.000 description 7
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229960001948 caffeine Drugs 0.000 description 7
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 230000001502 supplementing effect Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000009102 absorption Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 230000034659 glycolysis Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000009469 supplementation Effects 0.000 description 6
- 206010002660 Anoxia Diseases 0.000 description 5
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229950006238 nadide Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 102000001105 Phosphofructokinases Human genes 0.000 description 4
- 108010069341 Phosphofructokinases Proteins 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 150000005693 branched-chain amino acids Chemical class 0.000 description 4
- 230000037080 exercise endurance Effects 0.000 description 4
- 230000004110 gluconeogenesis Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 235000011496 sports drink Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- 230000002929 anti-fatigue Effects 0.000 description 3
- 230000000386 athletic effect Effects 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 159000000003 magnesium salts Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004220 muscle function Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 235000020733 paullinia cupana extract Nutrition 0.000 description 3
- 235000019710 soybean protein Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 208000000412 Avitaminosis Diseases 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000005976 Citrus sinensis Nutrition 0.000 description 2
- 240000002319 Citrus sinensis Species 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010021135 Hypovitaminosis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000013009 Pyruvate Kinase Human genes 0.000 description 2
- 108020005115 Pyruvate Kinase Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 230000037354 amino acid metabolism Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- 230000037147 athletic performance Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 210000004536 heart mitochondria Anatomy 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004973 motor coordination Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 230000004783 oxidative metabolism Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000014268 sports nutrition Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000030401 vitamin deficiency disease Diseases 0.000 description 2
- IBPDKUYWDGDBQW-UHFFFAOYSA-N (1-hydroxy-3-phosphonooxypropan-2-yl) dihydrogen phosphate Chemical compound OP(=O)(O)OC(CO)COP(O)(O)=O IBPDKUYWDGDBQW-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000276331 Citrus maxima Species 0.000 description 1
- 235000001759 Citrus maxima Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229930189936 Glyoxalase Natural products 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YCWICGZNCWNNLP-PWVOXRODSA-N [Na].[Na].[Na].O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)C(=O)COP(O)(O)=O Chemical compound [Na].[Na].[Na].O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)C(=O)COP(O)(O)=O YCWICGZNCWNNLP-PWVOXRODSA-N 0.000 description 1
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002361 ketogenic effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000016237 mineral rich food Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012257 stirred material Substances 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种运动营养组合物及其制备方法,涉及运动营养食品或运动饮料技术领域。其包括如下所示的原料:1,6‑二磷酸果糖三钠盐、烟酰胺单核苷酸、瓜拉钠提取物、茅根提取物、芦根提取物、大豆肽、小麦低聚肽、复合氨基酸、复合维生素、碳水化合物、中链甘油三酯微囊粉、肌酸、牛磺酸和复合矿物质。本发明提供的运动营养组合物不仅包含运动人群所需的基本营养素,而且通过调节能量代谢,完善运动状态下机体的抗氧化系统、改善肌肉状态等方面来提升运动能力,防止或延缓疲劳的产生,改善运动耐力。
Description
技术领域
本发明涉及运动营养食品或运动饮料技术领域,具体而言,涉及一种运动营养组合物及其制备方法。
背景技术
随着我国全民健身运动的不断推进,社会大众健康意识得到进一步提升,群众性体育活动得到进一步推广。人们开展体育锻炼后,机体会出现运动性疲劳,若不关注运动疲劳,不及时消除疲劳,不仅不利于运动能力的提升,还会诱发运动性损伤和疾病,对运动人群的身心健康构成威胁。
近年来,随着体育竞技运动水平的飞速提高,越来越多的人在研究能显著提高运动能力的方法。而1,6-二磷酸果糖三钠盐是葡萄糖经细胞内葡萄糖激酶代谢生成的环状化合物。它作为细胞内代谢的中间产物,能改善细胞能量的供给,加速ATP的生成,改善机体在疲劳状态下的抗缺氧能力,提高运动员的运动能力,从而提升运动员机体的有氧供能能力,有助于运动员赛中和赛后的机体恢复。
机体新陈代谢所产生的自由基可造成机体损伤。正常情况下,机体存在着完善的抗氧化系统来清除自由基,但过强的运动强度或过长的运动时间,机体内的抗氧化剂不足以清除运动产生的自由基,导致体内的自由基水平居于较高水平,对组织造成损伤,导致运动性疲劳。
目前,市面上常见的一些运动营养食品或运动饮料基本上是添加肌酸、葡萄糖、蛋白质、维生素、矿物质等基本营养素,在提高运动能力和缓解疲劳的功效上作用不明显,个性化特点不明确,产品质量良莠不齐。
鉴于此,特提出本发明。
发明内容
本发明的目的在于提供一种运动营养组合物及其制备方法以解决上述技术问题。
本发明是这样实现的:
一种运动营养组合物,其包括如下重量份数的原料:1,6-二磷酸果糖三钠盐20-45份、烟酰胺单核苷酸50-65份、瓜拉钠提取物10-40份、茅根提取物120-160份、芦根提取物80-110份、大豆肽130-160份、小麦低聚肽130-160份、复合氨基酸340-380份、复合维生素6-11份、碳水化合物475-520份、中链甘油三酯微囊粉175-210份、肌酸185-220份、牛磺酸9-17份和复合矿物质1-5份。
本发明提供的运动营养组合物不仅包含运动人群所需的基本营养素,而且还含有有助于提升运动能力、缓解运动性疲劳、抗氧化的组分。本发明提供的运动营养组合物是结合现代营养学、细胞生物学及中医养生理论开发出的一款运动营养食品。
本发明通过改善能量供给,提高了机体的抗缺氧能力,通过完善运动状态下机体的抗氧化系统等方面来提升运动能力,增加运动耐力,防止或延缓疲劳的产生,促进了运动性疲劳的恢复。从中医的整体观念出发,改善了剧烈运动及较高的心理压力下运动员的免疫系统,提高了运动员的免疫力和耐缺氧能力,同时也提高了运动员的机体抗氧化能力。
本发明提供的运动营养组合物选用多种生物利用度高、吸收快的营养物质,如大豆肽、小麦低聚肽、中链甘油三酯、复合矿物质等。选用快速吸收的营养物质可以减少胃肠的负担。本发明提供的复合矿物质与人体汗液中的电解质比例相当,有助于快速恢复体液电解质的平衡。而组合物中的复合维生素和复合氨基酸均有助于提高运动能力和促进疲劳的消除。组合物中的多种糖类,起到分时段补充能量,稳定血糖水平,促进胰岛素的平衡,预防肥胖和糖尿病发生的作用。
具体地,运动员在结束高强度的训练和比赛后,身体组织特别是运动肌处于不同程度的缺血状态,需要增加氧供,消除血乳酸,以缓解运动疲劳。糖酵解是生物界普遍存在的最原始的供能途径,是短时间高强度剧烈运动时的主要能量来源。糖酵解的最后产物是乳酸,乳酸是酸性物质,生成过多会导致肌肉的酸碱度下降,致使磷酸果糖激酶的活性受到抑制,从而抑制糖酵解的速度,造成机体能源物质补充不足。
1,6-二磷酸果糖三钠盐既是磷酸果糖激酶反应的产物,也是磷酸果糖激酶的变构激活剂,还是丙酮酸激酶的变构激活剂。通过补充1,6-二磷酸果糖三钠盐,激活磷酸果糖激酶和丙酮酸激酶,刺激糖酵解加速葡萄糖分解,抑制糖异生途径,促进糖的利用,起到调节能量代谢的作用。1,6-二磷酸果糖三钠盐还可引起2,3-二磷酸甘油浓度的增加,有助于血红蛋白和组织之间的氧交换,有利于提高组织对氧的利用,提高有氧代谢供能能力,从而改善运动耐力。
烟酰胺单核苷酸(简称NMN)在人体细胞能量生成中扮演着重要角色,参与细胞内烟酰胺腺嘌呤二核苷酸的合成。NMN是NAD+的前体,NAD+又名辅酶I,广泛分布在人体的所有细胞内,参与上千种生化催化反应,是人体内必不可少的辅酶。NMN可以通过增强三羧酸循环和电子传递链的代谢通量,减少细胞中活性氧的积累,以及增加还原态烟酰胺腺嘌呤二核苷磷酸(NADPH)水平,维持谷胱甘肽和硫氧还原蛋白抗氧化系统,增强骨骼肌中线粒体的氧化代谢,增加运动耐力。
烟酰胺单核苷酸可间接保护心脏、改善肌肉功能和运动协调能力。补充NMN后在体内合成NAD+,从而激活脱乙酰基酶(SIRT1)蛋白。SIRT1蛋白是一种NAD+依赖的组蛋白脱乙酰化酶,当体内NAD+不足时,SIRT1使赖氨酸残基脱乙酰基,有助于产生活性氧自由基。这种机制诱发氧化应激,引起再灌注或缺血性损伤。在缺血现象发生之前或已经出现缺血时,补充NMN可通过糖酵解提高ATP的产生来提供心脏保护作用。除此之外,激活SIRT1蛋白还可以改善肌肉功能和运动协调能力。本发明通过补充外源性烟酰胺单核苷酸可以减少细胞中活性氧的积累,从而降低高强度运动时高水平氧自由基对机体的损伤,防止或延缓疲劳的产生,从而提高运动能力。
瓜拉钠主要产自亚马逊流域,瓜拉钠提取物中的主要功效成分为瓜拉钠因子,其化学成分与咖啡因类似,是优质的天然咖啡因的来源之一,具有提神醒脑、缓解腹痛、恢复体力、补充能量、提高人体机能的作用。瓜拉钠中所含的天然咖啡因与各种植物本身内在的多酚类物质以复合形式存在,可以温和而持久地刺激神经。而人工合成咖啡因起效迅速,但持续时间短,副作用大,会导致心慌、焦虑等症状。一些咖啡因上瘾的患者,常常容易激动,有攻击性,也有睡眠障碍和注意力集中障碍。研究表明,减少咖啡因的摄取,服用瓜拉纳后,在数周内上述症状消失了。由此可知天然咖啡因对人体更为健康。
肌酸,是人体内自然产生的一种氨基酸衍生物,它可以快速增加肌肉力量,加速疲劳恢复,提高爆发力。肌酸在人体内储存越多,力量及运动能力也越强。肌酸存在于鱼、肉等食物中,但数量很少,要达到每日所需的摄入量,需要吃下大量的肉,现实生活中是不可能的,因此需要额外补充。
与蛋白质相比,多肽不需要消化即可促使机体快速吸收,降低胃肠功能负担。大豆肽是大豆蛋白经生物酶解后的小分子蛋白,保留了大豆蛋白的全价氨基酸组成,又比大豆蛋白具有更快吸收、完全吸收、低致敏、无嘌呤等优势。补充大豆肽有助于增加肌肉、提高肌肉力量、提高运动能力,若在运动后补充,有助于恢复体能,修复肌肉纤维。
小麦低聚肽中含有超过20%的谷氨酰胺。在饥饿、酸中毒及过量运动等应激状态下,人体对谷氨酰胺的需求量远超过体内合成谷氨酰胺的能力,因此对于长期大量运动的人群而言,谷氨酰胺是必需氨基酸。适量补充谷氨酰胺能有效防止肌肉蛋白的分解,并可通过细胞的水合作用,增加细胞的体积,促进肌肉的增长。与谷氨酰胺相比,小麦低聚肽稳定性更高。除此之外,小麦低聚肽还可以减少心肌线粒体氧自由基的生成,维持心肌线粒体的正常形态结构和功能,提高耐缺氧能力,起到降低疲劳感的作用。
中链甘油三酯(MCT)是由中链脂肪酸构成的甘油三酯,因其独特的理化特性,使得MCT在机体内的消化、吸收、转运和代谢不同于长链脂肪酸,其在体内消化代谢的速度与葡萄糖相当,且产生的能量是葡萄糖产生的能量的2倍。MCT具有快速消化吸收,氧化代谢的特点。MCT具有一般植物油所不具有的独特的功能性质。MCT提高运动耐力的机制有:在长时间有氧耐力运动中,脂肪分解代谢是主要的能源物质;脂肪作为能源物质被动员的能力提高可以降低对糖类和蛋白质的消耗,维持血糖的相对稳定,提高运动能力,减缓疲劳的发生;MCT具有较强的生酮作用,生成的酮体可以作为长时间运动时大脑及肌肉等组织的补充能源物质,减少对血糖的消耗。
牛磺酸是一种含硫氨基酸,可以加速机体内自由基的清除速度,可显著降低机体的脂质过氧化水平。补充牛磺酸能够降低机体对血糖的利用程度,同时促进肌细胞对糖和氨基酸的摄入和利用,加速糖酵解的速度,增加糖异生的底物浓度,从而促进机体糖原的合成,减少运动性疲劳的发生,提高运动能力。
维生素是人体所需要的7大类营养素中最容易缺乏的一类,运动人群又属于维生素缺乏症的高发人群;而维生素缺乏不仅可导致运动能力下降;还会进一步影响健康水平。
无论是力量性还是耐力性的长期训练,均会对氨基酸代谢产生深刻影响。运动会使氨基酸代谢加强,利用率增高,因此对于运动人群,氨基酸也是重要的补充剂。
中医认为运动性疲劳属于中医学“劳倦”、“虚损”等范畴。《杂病广要-虚劳篇》指出“凡虚损之由,无非劳倦七情饮食所致,或先伤其气,气伤必及精”,现代运动属于“劳”的范畴。我国传统的中药在抗疲劳方面有着其独特的优势。在疲劳的恢复方面,注重整体观念和辨证施治相结合,重视人体自身的一个抗疲劳能力,发挥中医药整体疗法的优势。剧烈运动及较高的心理压力会抑制运动员体内的免疫系统。随着竞技等级或水平的提高,身心的压力将更大,因而发生病毒感染的概率也相应的增大。本申请中添加芦根和茅根提取物以提升机体的抗氧化能力,减少高强度运动时氧自由基的损伤,防止或延缓疲劳的产生。
芦根,味甘,性寒,归肺、胃经,主治清热泻火、生津止渴,除烦,止呕,利尿。芦根生于水中,清热透热,可清肺部之壅结。临床上芦根具有解热、镇痛、提高免疫力、降压、镇静、抗肿瘤等作用,可治疗感冒、支气管炎急性扁桃体腺炎、肺脓疡等疾病。芦根提取物,主要成分为多糖,还含有少量黄酮类、甾体类、蒽醌类、生物碱、小分子类等成分。芦根提取物具有较好的细胞免疫功能增强作用,可提高运动员的免疫力。
茅根,又名白茅根,性味甘寒,归肺、胃和膀胱经,具有凉血止血、清热利尿之功。茅根提取物主要成分为三萜类和多糖,具有提高机体耐缺氧能力的作用。对于运动员来说,耐缺氧能力提高,可增加肺的通气量和弥散度,加速氧气的传递,提高氧气的利用率,从而延缓疲劳的发生。茅根提取物还具有免疫调节作用,可增强细胞免疫功能,调节人外周T淋巴细胞免疫功能。
在本发明应用较佳的实施方式中,上述复合氨基酸包括如下重量比的原料:L-天门冬氨酸、精氨酸、L-亮氨酸、L-异亮氨酸和L-缬氨酸的比例为1-4:2-5:9-12:3-5:4-7;
优选地,L-天门冬氨酸、精氨酸、L-亮氨酸、L-异亮氨酸和L-缬氨酸的比例为1:3:10:5:5。
L-天门冬氨酸是一种较好的抗疲劳物质,具有加强脂肪酸氧化、加速肌肉中ATP-CP和糖原合成的作用,从而减少糖原的消耗,预防疲劳的发生。
精氨酸能促进人体生长素的释放,也是肌酸生成所必须的物质,因此补充精氨酸有助于减少身体脂肪、提高肌肉质量。精氨酸可以促进鸟氨酸循环,把由于运动消耗蛋白质而产生过多的氨转化为尿素,防止血氨的升高,从而提高运动能力。
L-亮氨酸、L-异亮氨酸、L-缬氨酸是必需氨基酸,因其分子组成中都有支链又被称为支链氨基酸。支链氨基酸具有抗中枢性疲劳、抗外周性疲劳的作用,可延缓运动性疲劳,加速运动后机体的修复。另外补充支链氨基酸还可促进糖异生作用,减少骨骼肌乳酸的积累,延缓疲劳的发生,促进运动后疲劳的消除。在上述添加比例下,延缓运动性疲劳效果最佳。
在本发明应用较佳的实施方式中,上述复合维生素为维生素B1、维生素B2、维生素B6、维生素B12、烟酰胺、维生素C和维生素E中的至少一种;
优选地,复合维生素为维生素B1、维生素B6、维生素C和维生素E;优选地,维生素B1、维生素B6、维生素C和维生素E的重量比例为1-4:1-5:160-200:25-40;
优选地,维生素B1、维生素B6、维生素C和维生素E的重量比例为2:1:175:35。
维生素B1是糖代谢中丙酮酸等氧化脱羧所必需的辅酶的组成部分,与神经介质乙酰胆碱的合成分解有关,参与神经肌肉的正常传导功能。运动训练时,若缺乏维生素B1,会导致丙酮酸、乳酸的累积,造成机体疲劳,同时乳酸脱氢酶、乙二醛酶活性下降,从而影响心脏功能。
维生素B6进入人体内主要以辅酶的形式发挥作用,可以通过促进血红蛋白的生成与糖异生作用、减少乳酸生成等生化途径,缓解运动疲劳,提高运动员的运动能力。
补充维生素C可以防止肌细胞受损、缓解肌肉酸痛,促进运动后肌肉的恢复。同时,维生素C有助于提高机体的抗氧化能力,预防运动性贫血。
当机体中缺乏维生素E时,可导致肌肉营养不良及神经系统的供能异常。补充维生素E,其超强的抗氧化功能,可改善循环系统,促进蛋白质的合成,防止肌肉萎缩。
在上述添加配比下,可以有效提升运动员的机体抗氧化能力,缓解运动疲劳,提高运动员的运动能力。
在本发明应用较佳的实施方式中,上述碳水化合物为白砂糖、葡萄糖、低聚异麦芽糖、低聚麦芽糖、结晶果糖和麦芽糊精中的至少一种;
优选地,碳水化合物为白砂糖、葡萄糖、低聚麦芽糖和结晶果糖;优选地,白砂糖、葡萄糖、低聚麦芽糖和结晶果糖的重量比例为4-7:1-4:2-5:1-4;
优选地,白砂糖、葡萄糖、低聚麦芽糖和结晶果糖的重量比例为5:2:2:1。
糖在体内主要以糖原的形式贮存,糖是既能进行有氧代谢,又是唯一能无氧代谢合成ATP的细胞原料,是运动时人体最主要的能源利用物质。运动补糖有利于能量平衡、帮助尽快缓解疲劳和促进体力恢复,加强肝糖原和肌糖原的合成和储存。
补充蔗糖和葡萄糖后,机体迅速吸收,可快速补充能量,但补充过多会提高胰岛素的浓度,导致肥胖和糖尿病。
低聚麦芽糖,具有易消化、低甜度、低渗透特性,可延长供能时间,增强肌体耐力,抗疲劳等功能,人体经过长时间的剧烈运动后易出现脱水,能源储备,消耗血糖降低,体温高,肌肉神经传导受影响,脑功能紊乱等一系列生理变化和症状,而食用低聚麦芽糖后,不仅能保持血糖水平,减少血乳酸的产生,而且使胰岛素平衡。
果糖是一种天然单糖,是天然糖中甜度最高的糖。因其升糖指数低,代谢慢,要在超长一段时间后才可提供能量,与葡萄糖搭配使用可以降低整体的血糖应答。
因此本发明提供的组合物中的多种糖类可以起到分时段补充能量的作用,延长供能时间,并且可降低肥胖和糖尿病发生的可能性。
在本发明应用较佳的实施方式中,上述复合矿物质为氯化钾、乳矿物盐和海水镁中的至少一种;
优选地,氯化钾、乳矿物盐和海水镁的重量比例为3-5:7-9:2-4;
优选地,氯化钾、乳矿物盐和海水镁的重量比例为5:8:2。
在本发明应用较佳的实施方式中,上述1,6-二磷酸果糖三钠盐与氯化钾的重量比例为70-100:1;
优选地,1,6-二磷酸果糖三钠盐与所述氯化钾的重量比例为90:1。
人体体液中的水分和电解质会随着汗液的流失而流失,机体会调动储存的电解质,如果机体电解质储备不足,就会影响各个依赖这些电解质的器官,进而破坏体液的渗透压平衡。因此,在运动过程中,补充电解质和补充水分同样重要。产品中添加1,6-二磷酸果糖三钠盐、氯化钾、乳矿物盐和海水镁多种富含矿物质的食品原料。四种原料特定的比例与人体汗液中电解质比例相当,在运动后补充可改善身体的缺水状况,使体液中的电解质恢复平衡。
乳矿物盐是以乳清为原料,去除蛋白质、乳糖等成分而制得的有利于人体吸收的营养补充剂。与无机钙相比,乳矿物盐对胃肠刺激小、生物利用度高,可被人体有效吸收与利用,与人体骨骼、牙齿的组成接近,合理的钙磷比例比单纯补钙效果更好。
海水是重要的天然镁来源,主要形式为MgCl2、MgSO4,提取后的海水镁能够确保这些镁盐的浓缩物仍然保留其在海水中的天然形式,与化学合成的镁盐相比,海水镁生物利用度高,且含有铁、锌、锂、锶、磷等多种人体所需的矿物质。
在本发明应用较佳的实施方式中,上述茅根提取物和芦根提取物均为水提物。
制备固态食品时,采用等量递增的混合方式。即按照添加物质的重量份数由低到高依次添加。这种混合方式,可以保证添加量较少的组分(如维生素,复合矿物质)能充分混匀。
运动营养组合物固体制剂制备方法包括如下步骤:先分别等量递增混合维生素和矿物质,得到复合维生素和复合矿物质,然后将复合维生素和复合矿物质与1,6-二磷酸果糖三钠盐、烟酰胺单核苷酸、瓜拉钠提取物、茅根提取物、芦根提取物、大豆肽、小麦低聚肽、复合氨基酸、碳水化合物、中链甘油三酯微囊粉、肌酸和牛磺酸按比例等量递增混合。
在其他实施方式中,为获得较好的口感,固体制剂还可添加水果粉(刺梨粉、苹果粉、蓝莓粉、甜橙粉、葡萄粉、石榴粉、西柚粉和柠檬粉中的一种或多种)。
当运动营养组合物制备成运动饮料时,制备过程包括如下步骤:
将碳水化合物、复合维生素、复合矿物质、1,6-二磷酸果糖三钠盐、烟酰胺单核苷酸、瓜拉钠提取物、茅根提取物、芦根提取物、大豆肽、小麦低聚肽、复合氨基酸、中链甘油三酯微囊粉、肌酸和牛磺酸与水混合。
优选地,先将475-520份的碳水化合物溶解,然后将水与溶解后的碳水化合物混合,继续加入复合维生素、复合矿物质、1,6-二磷酸果糖三钠盐、烟酰胺单核苷酸、瓜拉钠提取物、茅根提取物、芦根提取物、大豆肽、小麦低聚肽、复合氨基酸、中链甘油三酯微囊粉、肌酸和牛磺酸得到混合液。
在其他实施方式中,也可以预先将待添加的复合维生素、复合矿物质、1,6-二磷酸果糖三钠盐、烟酰胺单核苷酸、瓜拉钠提取物、茅根提取物、芦根提取物、大豆肽、小麦低聚肽、复合氨基酸、中链甘油三酯微囊粉、肌酸和牛磺酸进行分别预溶解,然后再加入至溶解的碳水化合物中。
在本发明应用较佳的实施方式中,上述运动饮料的制备还包括将混合液中加入果汁和添加剂;
优选地,果汁为蓝莓汁、葡萄汁、橙汁、柠檬汁、西柚汁、芒果汁和水蜜桃汁中的至少一种。
优选地,添加剂为柠檬酸、柠檬酸钠、苹果酸和香精。
优选地,将加入果汁和添加剂后的料液进行灭菌,灌装。
优选地,灭菌是在123-125℃下,3-5s高温瞬时灭菌。
本发明具有以下有益效果:
本发明提供的运动营养组合物不仅包含运动人群所需的基本营养素,而且还含有有助于提升运动能力、缓解运动性疲劳、抗氧化的组分。本发明提供的运动营养组合物是结合现代营养学、细胞生物学及中医养生理论开发出的一款运动营养食品。
本发明通过改善能量供给,提高了机体的抗缺氧能力,通过完善运动状态下机体的抗氧化系统等方面来提升运动能力,防止或延缓疲劳的产生,促进了运动性疲劳的恢复。从中医的整体观念出发,改善了剧烈运动及较高的心理压力下运动员的免疫系统,提高了运动员的免疫力和耐缺氧能力,同时也提高了运动员的机体抗氧化能力。
运动营养组合物的制备方法简单易行,便于大规模的工业化生产。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将对本发明实施例中的技术方案进行清楚、完整地描述。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
以下结合实施例对本发明的特征和性能作进一步的详细描述。
实施例1
本实施例提供了一种运动营养组合物。其包括如下重量份数的原料:
1,6-二磷酸果糖三钠盐:20份;
烟酰胺单核苷酸:50份;
瓜拉钠提取物:10份;
茅根水提取物:120份;
芦根水提取物:80份;
大豆肽:130份;
小麦低聚肽:130份;
复合氨基酸(L-天门冬氨酸、精氨酸、L-亮氨酸、L-异亮氨酸和L-缬氨酸比例为1:3:10:5:5):340份;
复合维生素(维生素B1、维生素B6、维生素C、维生素E,比例为2:1:175:35):6份;
碳水化合物(白砂糖、葡萄糖、低聚麦芽糖和结晶果糖的比例为5:2:2:1):475份;
中链甘油三脂微囊粉:175份;
肌酸:185份;
牛磺酸:9份;
复合矿物质(氯化钾、乳矿物盐、海水镁比例为5:8:2):1份。
本实施例提供了一种固态运动营养组合物的制备方法,其包括按照本实施例提供的配方分别混合各原料。先分别混合维生素、矿物质,得到复合维生素、复合矿物质。然后再与其余物料按比例混合均匀,装袋。
实施例2
本实施例提供了一种运动营养组合物。其包括如下重量份数的原料:
1,6-二磷酸果糖三钠盐:40份;
烟酰胺单核苷酸:60份;
瓜拉钠提取物:30份;
茅根水提取物:140份;
芦根水提取物:90份;
大豆肽:150份;
小麦低聚肽:140份;
复合氨基酸(L-天门冬氨酸、精氨酸、L-亮氨酸、L-异亮氨酸和L-缬氨酸比例为1:3:10:5:5):360份;
复合维生素(维生素B1、维生素B6、维生素C、维生素E,比例为2:1:175:35):8份;
碳水化合物(白砂糖、葡萄糖、低聚麦芽糖和结晶果糖的比例为5:2:2:1):500份;
中链甘油三脂微囊粉:190份;
肌酸:200份;
牛磺酸:12份;
复合矿物质(氯化钾、乳矿物盐、海水镁比例为5:8:2):3份。
本实施例提供了一种固态运动营养组合物的制备方法,其包括按照本实施例提供的配方分别混合各原料。先分别混合维生素、矿物质,得到复合维生素、复合矿物质。然后再与其余物料按比例混合均匀,装袋。
实施例3
本实施例提供了一种运动营养组合物。其包括如下重量份数的原料:
1,6-二磷酸果糖三钠盐:45份;
烟酰胺单核苷酸:65份;
瓜拉钠提取物:40份;
茅根水提取物:160份;
芦根水提取物:110份;
大豆肽:160份;
小麦低聚肽:160份;
复合氨基酸(L-天门冬氨酸、精氨酸、L-亮氨酸、L-异亮氨酸和L-缬氨酸比例为1:3:10:5:5):380份;
复合维生素(维生素B1、维生素B6、维生素C、维生素E,比例为2:1:175:35):11份;
碳水化合物(白砂糖、葡萄糖、低聚麦芽糖和结晶果糖的比例为5:2:2:1):520份;
中链甘油三脂微囊粉:210份;
肌酸:220份;
牛磺酸:17份;
复合矿物质(氯化钾、乳矿物盐、海水镁比例为5:8:2):5份。
本实施例提供了一种固态运动营养组合物的制备方法,其包括按照本实施例提供的配方分别混合各原料。先分别混合维生素、矿物质,得到复合维生素、复合矿物质。然后再与其余物料按比例混合均匀,装袋。
实施例4
本实施例提供了一种固态运动营养食品的制备方法,其包括按照实施例1提供的配方分别混合各原料。先分别混合维生素、矿物质,得到复合维生素、复合矿物质。然后再与其余物料按比例混合均匀,装袋。为获得较好的口感,固体制剂中还添加有刺梨粉。
实施例5
本实施例提供了一种固态运动营养食品的制备方法,其包括按照实施例1提供的配方分别混合各原料。先分别混合维生素、矿物质,得到复合维生素、复合矿物质。然后再与其余物料按比例混合均匀,装袋。为获得较好的口感,固体制剂中还添加有蓝莓粉、甜橙粉和葡萄粉。
实施例6
本实施例提供了一种运动饮料的制备方法,其包括先取少量饮用水将实施例2中的碳水化合物溶解,得到糖浆。再取总水量80%的饮用水,加入糖浆,搅拌,依次加入果汁、柠檬酸、柠檬酸钠、苹果酸、预先溶好的各种实施例2中的固体原料(包括1,6-二磷酸果糖三钠盐、复合维生素、复合矿物质、烟酰胺单核苷酸、瓜拉钠提取物、茅根提取物、芦根提取物、大豆肽、小麦低聚肽、复合氨基酸、中链甘油三酯微囊粉、肌酸和牛磺酸)以及香精,继续搅拌2min后加入饮用水,并定容至100%,再继续搅拌10min。搅拌好的料液经125℃,3s高温瞬时灭菌,冷却至80℃灌装,冷却即得运动饮料。
对比例1
本实施例与实施例1相比,区别仅在于不含烟酰胺单核苷酸,其余配方及制备方法与实施例1相同。
对比例2
本实施例与实施例1相比,区别仅在于不含小麦低聚肽,其余配方及制备方法与实施例1相同。
对比例3
本实施例与实施例1相比,区别仅在于不含芦根水提取物和茅根水提取物,其余配方及制备方法与实施例1相同。
实验例
1、负重游泳实验。
选体重18-20g成年雄性昆明种小鼠100只,按照样品随机分组,每组10只动物。各实验组每天灌胃给药,剂量为3000mg/kg。其中实施例6制得的运动饮料的灌胃剂量是以溶解前组合物的质量计(即实施例2中的组合物质量计),分别取相同质量的实施例1-5及对比例1-3制得的运动营养组合物溶于相等体积的蒸馏水制得液体灌胃剂进行灌胃给药,实施例6制得的运动饮料的溶液体积与实施例1的液体灌胃剂体积相等,设置1个阴性对照组,每天灌服等体积蒸馏水,连续给药30天。于末次给药30min后,将小鼠置于水深30cm,水温25±0.5℃的水箱中游泳,鼠尾根部负荷5%体重的铅皮。记录小鼠自游泳开始至死亡的时间,作为小鼠游泳时间。
实验结果参照表1所示,由表1可知:实施例1、对比例1、2、3各组小鼠负重游泳时间与阴性对照组相比,差异极显著(p<0.01),对比例1、2、3组小鼠负重游泳时间与实施例1组小鼠相比,差异极显著(p<0.01)。
2、血清尿素氮测定
小鼠100只,给药方式及分组同上。连续给药30天,于末次给药30min后,在温度为30℃的水中游泳90min后,眼球取血,肝素抗凝。按尿素氮BUN测试盒(上海荣盛)说明操作测定尿素氮。
各处理组的尿素氮水平参照表1所示,由表1可知:实施例1、对比例1、2、3各组小鼠血清尿素氮含量与阴性对照组相比,差异极显著(p<0.01),对比例1、2、3组小鼠血清尿素氮含量与实施例1组小鼠相比,差异极显著(p<0.01)。
3、肝糖原、超氧化物歧化酶(SOD)、丙二醛(MDA)
小鼠100只,给药方式及分组同上。于末次给药30min后,在温度为30℃的水中游泳90min后,立即处死,迅速取其肝脏,用生理盐水洗去血渍,用于测定小鼠肝脏中肝糖原、超氧化物歧化酶(SOD)、丙二醛(MDA)生化指标。采用蒽醌法测定肝糖原含量。按照超氧化物歧化酶(SOD)测定试剂盒(南京建成)和丙二醛(MDA)测定试剂盒(南京建成)说明分别测定SOD和MDA。
肝糖原水平参照表1所示,由表1可知:实施例1、对比例1、2、3各组小鼠肝糖原含量与阴性对照组相比,差异极显著(p<0.01),对比例1、2、3组小鼠肝糖原含量与实施例1组小鼠相比,差异极显著(p<0.01)。
超氧化物歧化酶(SOD)水平参照表2所示,实施例1、对比例1、2、3各组小鼠SOD水平极显著高于阴性对照组小鼠(p<0.01)。对比例1、2、3组小鼠SOD水平极显著低于实施例1组小鼠(p<0.01)。
丙二醛(MDA)水平参照表2所示,实施例1、对比例1、2、3各组小鼠MDA水平极显著低于阴性对照组小鼠(p<0.01)。实施例1组小鼠MDA水平极显著低于对比例2组小鼠(p<0.01),显著低于对比例1、对比例3两组小鼠(p<0.05)。
表1各处理组负重游泳时间、血清尿素氮、肝糖原水平。
注:与阴性对照组比较:**p<0.01,与实施例1比较:##p<0.01。
表2各处理组的超氧化物歧化酶(SOD)、丙二醛(MDA)生化指标。
组别 | SOD(U/mL) | MDA(nmol/mL) |
阴性对照组 | 70.28±3.37 | 6.38±0.42 |
实施例1 | 140.79±4.32** | 4.65±0.23** |
对比例1 | 97.97±5.47**## | 5.33±0.18**# |
对比例2 | 101.80±6.51**## | 5.52±0.28**## |
对比例3 | 97.18±5.67**## | 5.18±0.19**# |
注:与阴性对照组比较:**p<0.01,与实施例1比较:##p<0.01,#p<0.05。
表3实施例2-6处理组负重游泳时间、血清尿素氮、肝糖原水平。
注:实施例2-6处理组负重游泳时间、血清尿素氮及肝糖原水平与实施例1相比,无显著差异(p>0.05)。
表4实施例2-6的超氧化物歧化酶(SOD)、丙二醛(MDA)生化指标。
组别 | SOD(U/mL) | MDA(nmol/mL) |
实施例2 | 137.08±6.61 | 4.25±0.30 |
实施例3 | 135.57±5.66 | 4.13±0.38 |
实施例4 | 141.79±5.99 | 4.31±0.32 |
实施例5 | 136.10±5.89 | 4.20±0.29 |
实施例6 | 135.18±5.77 | 3.97±0.30 |
注:实施例2-6处理组SOD、MDA水平与实施例1相比,无显著差异(p>0.05)。
从上述试验数据(表3、表4以及表1-表2)可以看出,6组实施例和3组对比例均有延长小鼠负重游泳时间,减少疲劳小鼠尿素氮产生、促进糖原储备或减少糖原消耗、提高疲劳小鼠肝组织SOD水平,降低MDA水平的作用。
从实施例和对比例的数据差异可以看出,与组合物不含烟酰胺单核苷酸、小麦低聚肽或芦根、茅根提取物时相比,本发明提供的组合物,抗疲劳和抗氧化水平有显著提高。
本发明提供的运动营养组合物中,1,6-二磷酸果糖三钠盐与小麦低聚肽、维生素B1、维生素B6、支链氨基酸等组分是通过协同作用减少了运动产生的过多乳酸,改善了人体内环境;烟酰胺单核苷酸与维生素C、维生素E、芦根提取物、茅根提取物等通过完善机体的抗氧化系统、减少细胞内活性氧的积累,从而降低了高强度运动时高水平氧自由基对机体的损伤,延缓了疲劳的发生;1,6-二磷酸果糖三钠盐与牛磺酸、L-天门冬氨酸参与糖代谢,促进了糖原的合成,延缓了疲劳的发生;通过烟酰胺单核苷酸、肌酸、精氨酸、维生素E、大豆肽、小麦低聚肽的协同作用,有助于提高肌肉质量、增加肌肉力量、改善肌肉功能同时防止肌肉萎缩,从而提高运动能力。因此本发明运动营养组合物从多方位、多角度出发,通过减少乳酸积累、完善抗氧化系统、促进糖原合成、改善肌肉状态等作用,达到缓解运动性疲劳、提高运动能力、促进疲劳的恢复的目的。
以上所述仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种运动营养组合物,其特征在于,其包括如下重量份数的原料:1,6-二磷酸果糖三钠盐20-45份、烟酰胺单核苷酸50-65份、瓜拉钠提取物10-40份、茅根提取物120-160份、芦根提取物80-110份、大豆肽130-160份、小麦低聚肽130-160份、复合氨基酸340-380份、复合维生素6-11份、碳水化合物475-520份、中链甘油三酯微囊粉175-210份、肌酸185-220份、牛磺酸9-17份和复合矿物质1-5份。
2.根据权利要求1所述的运动营养组合物,其特征在于,所述复合氨基酸包括如下重量比的原料:L-天门冬氨酸、精氨酸、L-亮氨酸、L-异亮氨酸和L-缬氨酸的比例为1-4:2-5:9-12:3-5:4-7;
优选地,L-天门冬氨酸、精氨酸、L-亮氨酸、L-异亮氨酸和L-缬氨酸的比例为1:3:10:5:5。
3.根据权利要求1所述的运动营养组合物,其特征在于,所述复合维生素为维生素B1、维生素B2、维生素B6、维生素B12、烟酰胺、维生素C和维生素E中的至少一种;
优选地,所述复合维生素为维生素B1、维生素B6、维生素C和维生素E;优选地,维生素B1、维生素B6、维生素C和维生素E的重量比例为1-4:1-5:160-200:25-40;
优选地,维生素B1、维生素B6、维生素C和维生素E的重量比例为2:1:175:35。
4.根据权利要求1所述的运动营养组合物,其特征在于,所述碳水化合物为白砂糖、葡萄糖、低聚异麦芽糖、低聚麦芽糖、结晶果糖和麦芽糊精中的至少一种;
优选地,所述碳水化合物为白砂糖、葡萄糖、低聚麦芽糖和结晶果糖;优选地,所述白砂糖、葡萄糖、低聚麦芽糖和结晶果糖的重量比例为4-7:1-4:2-5:1-4;
优选地,所述白砂糖、葡萄糖、低聚麦芽糖和结晶果糖的重量比例为5:2:2:1。
5.根据权利要求1所述的运动营养组合物,其特征在于,所述复合矿物质为氯化钾、乳矿物盐和海水镁中的至少一种;
优选地,所述氯化钾、乳矿物盐和海水镁的重量比例为3-5:7-9:2-4;
优选地,所述氯化钾、乳矿物盐和海水镁的重量比例为5:8:2。
6.根据权利要求5所述的运动营养组合物,其特征在于,所述1,6-二磷酸果糖三钠盐与所述氯化钾的重量比例为70-100:1;
优选地,所述1,6-二磷酸果糖三钠盐与所述氯化钾的重量比例为90:1。
7.根据权利要求1所述的运动营养组合物,其特征在于,所述茅根提取物和芦根提取物均为水提物。
8.一种如权利要求1-7任一项所述的运动营养组合物的制备方法,其特征在于,所述制备方法包括将重量份数的各原料进行混合。
9.一种运动饮料的制备方法,其特征在于,所述运动饮料包括权利要求1-7任一项所述的运动营养组合物,所述运动饮料的制备方法包括将碳水化合物、复合维生素、复合矿物质、1,6-二磷酸果糖三钠盐、烟酰胺单核苷酸、瓜拉钠提取物、茅根提取物、芦根提取物、大豆肽、小麦低聚肽、复合氨基酸、中链甘油三酯微囊粉、肌酸和牛磺酸与水混合。
10.根据权利要求9所述的制备方法,其特征在于,所述运动饮料的制备方法包括如下步骤:先将475-520份的碳水化合物溶解,然后将水与溶解后的碳水化合物混合,继续加入复合维生素、复合矿物质、1,6-二磷酸果糖三钠盐、烟酰胺单核苷酸、瓜拉钠提取物、茅根提取物、芦根提取物、大豆肽、小麦低聚肽、复合氨基酸、中链甘油三酯微囊粉、肌酸和牛磺酸得到混合液;
优选地,所述运动饮料的制备还包括将所述混合液中加入果汁和添加剂;
优选地,所述果汁为蓝莓汁、葡萄汁、橙汁、柠檬汁、西柚汁、芒果汁和水蜜桃汁中的至少一种;
优选地,所述添加剂为柠檬酸、柠檬酸钠、苹果酸和香精;
优选地,将加入果汁和添加剂后的料液进行灭菌,灌装;
优选地,所述灭菌是在123-125℃下,3-5s高温瞬时灭菌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011036955.4A CN112137095A (zh) | 2020-09-27 | 2020-09-27 | 一种运动营养组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011036955.4A CN112137095A (zh) | 2020-09-27 | 2020-09-27 | 一种运动营养组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112137095A true CN112137095A (zh) | 2020-12-29 |
Family
ID=73894927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011036955.4A Pending CN112137095A (zh) | 2020-09-27 | 2020-09-27 | 一种运动营养组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112137095A (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112931876A (zh) * | 2021-03-29 | 2021-06-11 | 哈尔滨医科大学 | 一种复合营养素补充剂配方 |
CN113040308A (zh) * | 2021-04-21 | 2021-06-29 | 广州体育职业技术学院 | 一种功能性固体运动饮料 |
CN113057335A (zh) * | 2021-05-10 | 2021-07-02 | 刘双虎 | 一种运动后肌肉恢复的运动营养食品及其制备方法 |
CN113208117A (zh) * | 2021-06-03 | 2021-08-06 | 泰州职业技术学院 | 一种含有nmn和牛磺酸的组合物及其应用 |
EP4070799A1 (en) * | 2021-04-08 | 2022-10-12 | Nuvamid SA | Compositions for the improvement of sport performance |
CN115517358A (zh) * | 2022-08-18 | 2022-12-27 | 北京华靳制药有限公司 | 矫味剂组合物及包含其的饮品 |
CN116058506A (zh) * | 2023-02-28 | 2023-05-05 | 广东医科大学 | 含米糠脂肪烷醇的消除疲劳的组合物及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106617086A (zh) * | 2016-12-30 | 2017-05-10 | 贝克尔(天津)药业有限公司 | 一种增强运动能力和运动耐力的营养食品 |
CN107998370A (zh) * | 2017-12-08 | 2018-05-08 | 北京康比特体育科技股份有限公司 | 一种可增强机体运动能力且缓解运动疲劳的组合物 |
CN111166761A (zh) * | 2020-01-17 | 2020-05-19 | 南京医科大学 | 一类含有β-烟酰胺单核苷酸的盐制品及其应用 |
CN111346185A (zh) * | 2020-05-09 | 2020-06-30 | 南京圣诺生物科技实业有限公司 | 一种耐缺氧的中药组合物、制备方法和应用 |
-
2020
- 2020-09-27 CN CN202011036955.4A patent/CN112137095A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106617086A (zh) * | 2016-12-30 | 2017-05-10 | 贝克尔(天津)药业有限公司 | 一种增强运动能力和运动耐力的营养食品 |
CN107998370A (zh) * | 2017-12-08 | 2018-05-08 | 北京康比特体育科技股份有限公司 | 一种可增强机体运动能力且缓解运动疲劳的组合物 |
CN111166761A (zh) * | 2020-01-17 | 2020-05-19 | 南京医科大学 | 一类含有β-烟酰胺单核苷酸的盐制品及其应用 |
CN111346185A (zh) * | 2020-05-09 | 2020-06-30 | 南京圣诺生物科技实业有限公司 | 一种耐缺氧的中药组合物、制备方法和应用 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112931876A (zh) * | 2021-03-29 | 2021-06-11 | 哈尔滨医科大学 | 一种复合营养素补充剂配方 |
EP4070799A1 (en) * | 2021-04-08 | 2022-10-12 | Nuvamid SA | Compositions for the improvement of sport performance |
WO2022214455A1 (en) * | 2021-04-08 | 2022-10-13 | Nuvamid Sa | Compositions for the improvement of sport performance |
CN113040308A (zh) * | 2021-04-21 | 2021-06-29 | 广州体育职业技术学院 | 一种功能性固体运动饮料 |
CN113057335A (zh) * | 2021-05-10 | 2021-07-02 | 刘双虎 | 一种运动后肌肉恢复的运动营养食品及其制备方法 |
CN113208117A (zh) * | 2021-06-03 | 2021-08-06 | 泰州职业技术学院 | 一种含有nmn和牛磺酸的组合物及其应用 |
CN115517358A (zh) * | 2022-08-18 | 2022-12-27 | 北京华靳制药有限公司 | 矫味剂组合物及包含其的饮品 |
CN116058506A (zh) * | 2023-02-28 | 2023-05-05 | 广东医科大学 | 含米糠脂肪烷醇的消除疲劳的组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112137095A (zh) | 一种运动营养组合物及其制备方法 | |
US9522161B2 (en) | Performance enhancing composition and method of delivering nutrients | |
CN103918965B (zh) | 一种缓解体力疲劳的饮料 | |
US20030143311A1 (en) | Recovery drink formula and method | |
CN108651998A (zh) | 一种具有缓解疲劳功能的乳清蛋白粉及其制备方法 | |
BR0011277B1 (pt) | bebida desportiva compreendendo micronutrientes em combinação com aditivos convencionais para bebidas desportivas, tablete para a preparação de uma bebida desportiva e uso de lactobacilos. | |
CN102524872B (zh) | 一种参肽氨基酸饮料 | |
US8999424B2 (en) | Performance enhancing composition and method of delivering nutrients | |
AU2014292651B2 (en) | Anti-fatigue composition and use thereof | |
JPH09504945A (ja) | 新規飲料 | |
CN108606269B (zh) | 一种运动型营养补充剂及其制备方法 | |
CN109527313A (zh) | 一种可缓解视觉和体力疲劳的功能性饮料及其制备方法 | |
US20030104107A1 (en) | Energy drink formula and method | |
EP3977868A1 (en) | High-energy food supplement based on inverted sugars and ergogenic products for use in physical activity and method for producing same | |
CN110801018A (zh) | 辅酶q10维生素c运动含片 | |
CN106509540A (zh) | 一种增加免疫力并提高运动能力的饮料 | |
CN103621871B (zh) | 一种复合氨基酸保健品及其制备方法 | |
US20200054045A1 (en) | All-Natural Drink Composition for Synthesizing and Regenerating Adenosine Triphosphate (ATP) in Muscle Cells and Neurons, Repairing Exercise-Induced Muscle Fiber Damage, Repletion of Glycogen Stores in the Muscle and Liver, Enhancing Blood Flow to Tissue during Intense Exercise, and Preventing and Reducing Oxidative Damage to Tissues during Exercise with Minimal Gastrointestinal Disturbances | |
RU2529155C1 (ru) | Шоколад для спортивного питания "шокоспорт" | |
CN103126026A (zh) | 一种解酒饮料及制备方法 | |
Leutholtz et al. | Optimizing nutrition for exercise and sport | |
CN106723027A (zh) | 一种耐缺氧的营养组合物及其应用 | |
EP3984378A1 (en) | Dietary supplement for sport use | |
CN110522028A (zh) | 一种护肝抗疲劳的组合物及其应用 | |
CN109674842A (zh) | 一种离子维c奇异果组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201229 |
|
RJ01 | Rejection of invention patent application after publication |